Publication: Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing
4
Issued Date
2019-01-01
Resource Type
ISSN
18790070
07328893
07328893
Other identifier(s)
2-s2.0-85076547589
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diagnostic Microbiology and Infectious Disease. (2019)
Suggested Citation
Kritsada Pruksaphon, Akarin Intaramat, Kavi Ratanabanangkoon, Joshua D. Nosanchuk, Nongnuch Vanittanakom, Sirida Youngchim Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. Diagnostic Microbiology and Infectious Disease. (2019). doi:10.1016/j.diagmicrobio.2019.114959 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/52299
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing
Abstract
© 2019 Elsevier Inc. The pathogenic fungus Talaromyces (formerly Penicillium) marneffei is a thermally dimorphic fungus that can cause disseminated infection in patients with secondary immunodeficiency syndrome, in particular in the setting of advanced HIV infection. The areas of highest incidence are in Southeast Asia, Southern China, and Indian subcontinents. Talaromycosis (formerly penicilliosis) is identified as an AIDS-defining illness, and it has recently been recognized in non–HIV-associated patients with impaired cellular-mediated immunity. Microbiological culture is the gold standard method for the diagnosis of T. marneffei infection and usually requires up to 2–4 weeks for detectable growth to occur, which may result in a delay of appropriate treatment. Immunodiagnosis has become an alternative method for confirming talaromycosis. This article reviews various immunological tests for the diagnosis of talaromycosis, including a proposed novel rapid point-of-care assay using a new T. marneffei yeast phase-specific monoclonal antibody.